Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Frisell T, Hedberg S, Piehl F Ann Neurol. 2026 Jun 17. PMID: 42310849. Abstract CommentRecommendBookmarkWatch
